PLYX — Polaryx Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2075320 ·
Last close
$2.58
Market Cap
$122.15M
52W High
$9.18
52W Low
$2.33
ADV30
233,081
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,958,000 | -2,544,000 | 3,502,000 | 3,080,000 | 1,014,000 |
| Dec 2025 | 0 | — | -911,000 | -1,495,000 | 5,170,000 | 5,143,000 | 605,000 |
| Sep 2025 | 0 | — | -974,000 | -1,430,000 | 5,983,000 | 5,745,000 | 682,000 |
| Jun 2025 | 0 | — | -884,000 | -1,008,000 | 3,543,000 | 3,304,000 | 296,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,944,000
Investing CF
—
Financing CF
$4,466,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-99,635,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,821,000
Pretax Income TTM
$-8,985,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,821,000 | -8,985,000 | 5,170,000 | 605,000 | — | -3,944,000 |
| Dec 2024 | 0 | -4,352,000 | -30,356,000 | 5,001,000 | 289,000 | — | -2,573,000 |
| Dec 2023 | 0 | -3,781,000 | -3,779,000 | 2,315,000 | 1,038,000 | — | -173,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $123.50M | $1.16 | — |
| QTTB | Q32 Bio Inc. | $120.22M | $7.09 | — |
| INDP | Indaptus Therapeutics, Inc. | $125.70M | $1.11 | — |
| HSTC | HST Global, Inc. | $117.39M | $0.83 | — |
| VTVT | vTv Therapeutics Inc. | $130.61M | $33.16 | — |
News headlines (Yahoo Finance, 1h cache)
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
2026-05-14 13:15 · Yahoo
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
2026-04-23 12:30 · Yahoo
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
2026-04-21 12:30 · Yahoo
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
2026-04-15 13:15 · Yahoo
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
2026-04-01 12:30 · Yahoo
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
2026-03-17 12:30 · Yahoo
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
2026-03-12 12:30 · Yahoo
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
2026-02-27 13:30 · Yahoo
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
2026-02-17 13:30 · Yahoo
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
2026-02-10 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.